Consensus ResMed, Inc.

Equities

RMD

US7611521078

Advanced Medical Equipment & Technology

Market Closed - Nyse Other stock markets 21:00:02 08/12/2025 GMT			5-day change	1st Jan Change
250.04 ^USD	-2.54%		+0.67%	+9.34%

01:42am	Shares of Resmed Fall After Securing FDA Clearance for a Device Recommending Personalized Comfort Settings	MT
12-08	ResMed Receives FDA Clearance for AI-Powered Device to Personalize Sleep Apnea Therapy	MT

Evolution of the Average Target: ResMed, Inc.

Evolution of the Target Price: ResMed, Inc.

Changes in Analyst Recommendations: ResMed, Inc.

14.Ydt2dL5dDBddw8cAPJrS3UsMH1JYihJ2feZvso5DF3E.MZRAN_8obm4-8PZabuOfmiUhfWES-HsfDIwVwcI7VBMJnAUb2Wo6Tyj1oA~f2028d308dda21288dbb999b6ce18228

Analysts' recommendations: ResMed, Inc.

10-31	Baird Adjusts Price Target on ResMed to $300 From $320	MT
10-31	Jefferies & Co Adjusts ResMed Price Target to $285 From $290	MT
10-31	Wells Fargo Adjusts ResMed Price Target to $265 From $280	MT
10-31	Wolfe Research Adjusts ResMed Price Target to $225 From $215	MT
10-31	Morgan Stanley Adjusts ResMed Price Target to $305 From $304	MT
10-31	Mizuho Adjusts Price Target on ResMed to $300 From $310	MT
10-31	KeyBanc Adjusts Price Target on ResMed to $299 From $298	MT
10-31	RBC Lifts Price Target on ResMed to $303 From $300, Keeps Outperform Rating	MT
10-31	Morgan Stanley Lifts Price Target on ResMed to $305 From $304, Keeps Overweight Rating	MT
10-21	Morgan Stanley Adjusts Price Target on ResMed to $304 From $298, Maintains Overweight Rating	MT
10-15	Baird Adjusts Price Target on ResMed to $320 From $305, Maintains Outperform Rating	MT
10-14	Mizuho Adjusts Price Target on ResMed to $310 From $290, Maintains Outperform Rating	MT
10-14	PolyNovo Limited Announces Appointment of Robert Douglas to the Board of Directors	CI
09-18	Analyst recommendations: Autozone, Crowdstrike, Deere & Company, Micron Technology, MongoDB...
09-18	Citigroup Initiates ResMed at Buy With $330 Price Target	MT
08-18	CICC Adjusts Price Target on ResMed to $325 From $295, Maintains Outperform Rating	MT
08-01	JPMorgan Adjusts ResMed Price Target to $310 From $290, Maintains Overweight Rating	MT
08-01	Baird Adjusts ResMed Price Target to $305 From $283, Maintains Outperform Rating	MT
08-01	UBS Adjusts ResMed Price Target to $325 From $285, Maintains Buy Rating	MT
08-01	Piper Sandler Adjusts Price Target on ResMed to $270 From $248, Maintains Neutral Rating	MT
08-01	Stifel Adjusts Price Target on ResMed to $270 From $240, Maintains Hold Rating	MT
08-01	KeyBanc Adjusts Price Target on ResMed to $298 From $274, Maintains Overweight Rating	MT
08-01	Jefferies Adjusts Price Target on ResMed to $290 From $245, Maintains Hold Rating	MT
08-01	Wolfe Adjusts Price Target on ResMed to $215 From $200, Maintains Underperform Rating	MT
08-01	Mizuho Adjusts Price Target on ResMed to $290 From $270, Maintains Outperform Rating	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	RESMED, INC.					+14.39%
	THERMO FISHER SCIENTIFIC, INC.					+9.27%
	INTUITIVE SURGICAL, INC.					+3.65%
	DANAHER CORPORATION					+13%
	BOSTON SCIENTIFIC CORPORATION					+29.7%
	SIEMENS HEALTHINEERS AG					+31.22%
	EDWARDS LIFESCIENCES CORPORATION					+10.69%
	AGILENT TECHNOLOGIES, INC.					+16.43%
	GE HEALTHCARE TECHNOLOGIES INC.					+3.1%
	SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.					+38.37%
	Average					+16.98%
	Weighted average by Cap.					+14.33%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

250.04USD

Average target price

293.47USD

Spread / Average Target

+17.37%

High Price Target

335.00USD

Spread / Highest target

+33.98%

Low Price Target

225.00USD

Spread / Lowest Target

-10.01%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Baird
Jefferies & Co.
Wells Fargo Securities
Wolfe Research
Morgan Stanley
Mizuho Securities
KeyBanc Capital Markets
RBC Capital Markets
Citigroup
CICC Research
UBS
JPMorgan Chase
Stifel Nicolaus
Piper Sandler
Jarden Research
Oppenheimer
Needham & Co.
Evans & Partners
BofA Securities
JMP Securities
Goldman Sachs
Macquarie
J.P. Morgan Chase